LexDanaLexDanabeta
Inventor

Alfredo C. Castro

Inventor
Winchester, MA, US

Overview

94→
Patents
2001–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 94 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations28%
A61KPreparations for medical, dental or toiletry purposes24%
C07DHeterocyclic compounds23%
A61NElectrotherapy5%
C07JSteroids5%
Y02ATechnologies for adaptation to climate change4%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%
C07KPeptides3%
C07CAcyclic or carbocyclic compounds2%
C12NMicroorganisms or enzymes1%
PatentTitleYear
11,084,812RAD51 inhibitors202111,007,181Cyclopamine analogs202110,941,162Heterocyclic compounds and uses thereof202110,821,102Methods of use of cyclopamine analogs202010,696,650AHR inhibitors and uses thereof202010,689,388Indole AHR inhibitors and uses thereof202010,590,122RAD51 inhibitors202010,570,138Indole AHR inhibitors and uses thereof202010,406,139Cyclopamine analogs201910,336,746RAD51 inhibitors201910,329,299Heterocyclic compounds and uses thereof201910,314,827Methods of use of cyclopamine analogs201910,253,047Heterocyclic compounds and uses thereof201910,045,970Methods of use of cyclopamine analogs20189,951,083Cyclopamine analogs20189,828,377Heterocyclic compounds and uses thereof20179,775,844'Heterocyclic compounds and uses thereof'20179,751,888'Heterocyclic compounds and uses thereof'20179,738,644'Chemical compounds, compositions and methods for kinase modulation'20179,718,815'Heterocyclic compounds and uses thereof'20179,708,348'Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof'20179,669,011'Methods of use of cyclopamine analogs'20179,630,979'Inhibitors of monoacylglycerol lipase and methods of their use'20179,605,003'Heterocyclic compounds and uses thereof'20179,546,180'Heterocyclic compounds and uses thereof'20179,492,435'Cyclopamine analogs'20169,388,183'Heterocyclic compounds and uses thereof'20169,359,365'Heterocyclic compounds and uses thereof'20169,346,769'Tetrazolones as inhibitors of fatty acid synthase'20169,255,108'Heterocyclic compounds and uses thereof'20169,181,221'Chemical compounds, compositions and methods for kinase modulation'20159,149,465'Isoxazolines as inhibitors of fatty acid amide hydrolase'20159,145,422'Methods of use of cyclopamine analogs'20159,115,141'Substituted isoquinolinones and methods of treatment thereof'20159,108,989'Inhibitors of fatty acid amide hydrolase'20159,056,877'Heterocyclic compounds and uses thereof'20159,012,603'Peptides that block the binding of IgG to FcRn'20158,969,363'Heterocyclic compounds and uses thereof'20158,957,049'Inhibitors of fatty acid amide hydrolase'20158,940,742'Heterocyclic compounds and uses thereof'20158,927,551'Isoxazolines as inhibitors of fatty acid amide hydrolase'20158,901,133'Heterocyclic compounds and uses thereof'20148,895,576'Methods of use of cyclopamine analogs'20148,802,119'Inhibitors of fatty acid amide hydrolase'20148,802,064'Inhibitors of fatty acid amide hydrolase'20148,785,470'Heterocyclic compounds and uses thereof'20148,785,635'Cyclopamine analogs'20148,765,735'Isoxazolines as inhibitors of fatty acid amide hydrolase'20148,669,365'Cyclopamine analogs'20148,629,125'Inhibitors of fatty acid amide hydrolase'20148,609,706'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20138,604,032'Chemical compounds, compositions and methods for kinase modulation'20138,546,432'Tetrazolones as inhibitors of fatty acid synthase'20138,546,564'Inhibitors of fatty acid amide hydrolase'20138,541,581'Inhibitors of fatty acid amide hydrolase'20138,461,191'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20138,450,350'Triazoles as inhibitors of fatty acid synthase'20138,431,566'Cyclopamine lactam analogs and methods of use thereof'20138,426,436'Heterocyclic cyclopamine analogs and methods of use thereof'20138,349,814'Inhibitors of fatty acid amide hydrolase'20138,329,675'Inhibitors of fatty acid amide hydrolase'20128,304,428'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20128,293,760'Cyclopamine lactam analogs and methods of use thereof'20128,236,956'Cyclopamine analogues and methods of use thereof'20128,227,509'Methods of use of cyclopamine analogs'20128,178,690'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20128,101,186'Peptides that block the binding of IgG to FcRn'20128,017,648'Methods of use of cyclopamine analogs'20117,994,191'Heterocyclic cyclopamine analogs and methods of use thereof'20117,964,590'Cyclopamine lactam analogs and methods of use thereof'20117,947,663'Inhibitors of fatty acid amide hydrolase'20117,928,244'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20117,875,628'Cyclopamine analogues and methods of use thereof'20117,851,637'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20107,842,815'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20107,812,164'Cyclopamine analogs'20107,745,464'Compounds and methods for inhibiting the interaction of BCL proteins with binding partners'20107,727,985'Beta-carbolines useful for treating inflammatory disease'20107,648,994'Heterocyclic cyclopamine analogs and methods of use thereof'20107,407,967'Cyclopamine analogues and methods of use thereof'20087,348,336'Substituted β-carbolines'20087,230,004'Cyclopamine analogues and methods of use thereof'20077,026,331'Substituted beta-carbolines'20067,001,921'Cell adhesion inhibitors'20066,875,743'Cell adhesion inhibitors'20056,630,512'Cell adhesion inhibitors'20036,627,637'Substituted beta carbolines'20036,624,152'Cell adhesion inhibitors'20036,596,687'Cell adhesion inhibitors'20036,552,216'Molecular model for VLA-4 inhibitors'20036,376,538'Cell adhesion inhibitors'20026,306,840'Cell adhesion inhibitors'20016,248,713'Cell adhesion inhibitors'20016,239,108'Cell adhesion inhibitors'2001

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2001–2021Based in Woburn, MA, US· patent location history
2003–2020Based in Winchester, MA, US· patent location history
2005Based in Weburn, MA, US· patent location history
2008–2021Patents assigned to INFINITY PHARMACEUTICALS INC (60)· patent assignee history
2010–2015Patents assigned to CASTRO ALFREDO C (27)· patent assignee history
2010–2015Patents assigned to GROGAN MICHAEL J (19)· patent assignee history
2010–2015Patents assigned to SNYDER DANIEL A (17)· patent assignee history
2012–2015Patents assigned to EVANS CATHERINE A (12)· patent assignee history
2020Based in Somerville, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
INFINITY PHARMACEUTICALS INC602008–2021
CASTRO ALFREDO Cself272010–2015
GROGAN MICHAEL J192010–2015
SNYDER DANIEL A172010–2015
EVANS CATHERINE A122012–2015
Locations
LocationPatentsSpan
Winchester, Massachusetts, US622003–2020
Woburn, Massachusetts, US302001–2021
Somerville, Massachusetts, US12020
Weburn, Massachusetts, US12005